Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

RTTNews | 902 dias atrás
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

(RTTNews) - Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.

The products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir, Novolin, NovoLog and NovoLog Mix 70/30.

Novo Nordisk is also reducing the list price of unbranded biologics to match the lowered price of each respective branded insulin. These changes will go into effect on January 1, 2024.

Novo Nordisk currently provides co-pay support for a number of insulin products, meaning eligible patients can pay $25 to $35 for their insulin.

Novo Nordisk recognizes that some patients find it difficult to pay for healthcare, including insulin. As such, the Company remains committed to reducing the burden of out-of-pocket costs, helping transform the complex pricing system, and fostering better pricing predictability.

Novo Nordisk continually reviews and revises its offerings as well as works with diverse stakeholders to create solutions for differing patient needs.

Etiquetas: NVO
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews | 117 dias atrás
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews | 433 dias atrás
UK House Price Growth Softens In August

UK House Price Growth Softens In August

UK house prices logged a slower pace of growth in August due to stretched affordability, the Nationwide Building Society said Monday. House prices increased 2.1 percent on a yearly basis in August, slower than the 2.4 percent rise seen in July. On a monthly basis, house prices edged down 0.1 percent, in contrast to the 0.5 percent increase in the previous month.
RTTNews | 19 minutos atrás
Asian Shares Mixed After US Tech Selloff

Asian Shares Mixed After US Tech Selloff

Asian stocks turned in a mixed performance on Monday as China's factory activity data painted a mixed picture of the world's second-largest economy and investor enthusiasm for artificial intelligence waned.
RTTNews | 1 h 11 min atrás